7.870USD-1.50%Mkt Cap: 382.39M USDP/E: —Last update: 2026-05-22
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap382.39M USD
Enterprise Value120.97M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-83.86M USD
Revenue/Share—
Last Price7.870 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.80
PEG—
EV/EBITDA-1.35
EV/Revenue—
P/S—
P/B2.25
EPS (TTM)-3.55
EPS (Forward)-2.85
52W Range
1.47049% of range14.53
52W High14.53 USD
52W Low1.470 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.26%
ROA-64.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.75M USD
CapEx (TTM)2.59M USD
FCF Margin—
FCF Yield-12.80%
Net Debt-76.52M USD
Net Debt/EBITDA0.86
Balance Sheet
Debt/Equity0.10
Current Ratio8.16
Quick Ratio7.98
Book Value/Sh3.554 USD
Cash/Share3.511 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)35.80 USD
Target Range23.00 USD – 41.00 USD
# Analysts5
Ownership
Shares Out.48.59M
Float6.00M
Insiders11.19%
Institutions48.16%
Short Interest
Short Ratio0.7d
Short % Float2.27%
Short % Out.0.93%
Shares Short229.82K
Short (prev mo.)148.20K
Technical
SMA 508.564 (-8.1%)
SMA 2005.007 (+57.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)609.40K
Avg Vol (10d)1.09M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—